Re-Elevation of High-Sensitivity C-Reactive Protein but not the von Willebrand Factor After Withdrawing Atorvastatin Therapy in Patients With Unstable Angina Undergoing Coronary Artery Stenting A Kinetic Study

• Published in: International Heart Journal Vol. 47; no. 4; pp. 501 - 509
• Main Authors: Hang, Chi-Ling, Yip, Hon-Kan, Youssef, Ali A., Hung, Wei-Chin, Wu, Chiung-Jen, Chua, Sarah, Chen, Yen-Hsun, Yeh, Kuo-Ho
• Format: Journal Article
• Language: English
• Published: International Heart Journal Association 2006
• Subjects: Atorvastatin; Endothelial dysfunction; Inflammation
• ISSN: 1349-2365; 1349-3299
• DOI: 10.1536/ihj.47.501

Statins are known to reduce high-sensitivity C-reactive protein (hs-CRP) concentrations and improve endothelial function. However, whether statin withdrawal causes re-elevated concentrations of hs-CRP and von Willebrand Factor (vWF) (a marker of endothelial damage) remains unknown. We hypothesized that the concentrations of hs-CRP and vWF are substantially increased in patients with unstable angina pectoris (UAP) and noticeably decreased following coronary stenting along with atorvastatin therapy. However, re-elevations of these biomarker concentrations occurred once again after withdrawing atorvastatin therapy. We serially examined the plasma concentrations of hs-CRP and vWF in 51 patients with UAP before (day 0) and after (days 21, 90, 180, 270) performing coronary artery stenting. The concentrations of these 2 biomarkers were also measured in 30 healthy control subjects. Patients were treated with atorvastatin (40 mg/day orally) for 180 days, after which the therapy was withdrawn. The hs-CRP and vWF concentrations were significantly higher in the patients than in the healthy control subjects before the procedure (both P values < 0.001). The hs-CRP concentration decreased significantly on day 21 (P < 0.001), and further to a substantially lower level on day 180 (P < 0.0001). However, the hs-CRP level significantly increased again on day 270, as compared with that on day 180 (P < 0.001). The vWF plasma concentration decreased gradually to a significantly lower level on day 180. The concentration of this biomarker did not differ between days 180 and 270. In conclusion, although hs-CRP concentrations decreased markedly following combined stenting and atorvastatin therapy, re-elevation after atorvastatin therapy was withdrawn in UAP patients undergoing coronary stenting was not observed. Conversely, restoration of endothelial function was slow and persistent in these patients.